Phase I safety, pharmacokinetic (PK), and pharmacodynamic (PD) trial of NGR-hTNF given at high doses in patients with refractory solid tumors.
Paolo Andrea Zucali
No relevant relationships to disclose
Matteo Simonelli
No relevant relationships to disclose
Fabio De Vincenzo
No relevant relationships to disclose
Elena Lorenzi
No relevant relationships to disclose
Matteo Perrino
No relevant relationships to disclose
Monica Bertossi
No relevant relationships to disclose
Luca Balzarini
No relevant relationships to disclose
Cristina Bonifacio
No relevant relationships to disclose
Antonio Lambiase
Employment or Leadership Position - MolMed S.p.A.
Claudio Bordignon
Employment or Leadership Position - MolMed S.p.A.
Armando Santoro
No relevant relationships to disclose